Reply to “Matters arising: cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach”
Wen Hui,
Zhixiang Gao,
Min Zhu,
Huazhang Wu,
Yuanyi Cai
Affiliations
Wen Hui
Department of Science and Techonology, West China Hospital of Sichuan University
Zhixiang Gao
Department of Pharmacy, Affiliated Central Hospital of Shenyang Medical College
Min Zhu
Department of Health Service Management, School of Health Management, China Medical University
Huazhang Wu
School of Medical Humanities Sciences, China Medical University
Yuanyi Cai
Department of Health Service Management, School of Health Management, China Medical University
Abstract In this article, we read with great attention the correspondence by Bullement et al., regarding our published study on cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer. We referred to a few the most important comments from Bullement et al. in our opinion, including proportional hazard (PH) assumption, accelerated failure time (AFT) model, and health utility, and made some explanations.
